Necitumumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Necitumumab
Monoclonal antibody
Type Whole antibody
Source Human
Target EGFR
Clinical data
Trade names Portrazza
AHFS/Drugs.com Multum Consumer Information
Routes of
administration
Intravenous infusion
ATC code
Legal status
Legal status
Pharmacokinetic data
Biological half-life ~14 days
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6436H9958N1702O2020S42
Molar mass 144.84 kg/mol
 NYesY (what is this?)  (verify)

Necitumumab (INN) is a recombinant human IgG1 monoclonal antibody used as an antineoplastic. It binds to the epidermal growth factor receptor (EGFR).[1] The US FDA approved necitumumab under the brand name Portrazza for use with gemcitabine and cisplatin in previously untreated metastatic squamous non-small-cell lung carcinoma (NSCLC).[2][3][4] It was counterproductive in non-squamous non-small-cell lung carcinoma.[4][5]

References[edit]

  1. ^ International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
  2. ^ http://www.medscape.com/viewarticle/854952?nlid=91969_3663&src=wnl_edit_newsal&uac=78316PX&impID=899999&faf=1
  3. ^ http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm474278.htm
  4. ^ a b http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125547s000lbl.pdf
  5. ^ http://www.medscape.com/viewarticle/840768